Immix Biopharma, Inc. 8-K

What Happened

• On May 21, 2026, Immix Biopharma (IMMX) filed an 8-K and issued a press release disclosing an update from its Phase 2 NEXICART-2 trial of NXC-201 in relapsed/refractory light chain (AL) amyloidosis. The company reported that the four MRD-negative patients it previously announced at ASH 2025 have converted to complete response (CR).
• Among the first 20 patients in NEXICART-2, all MRD-negative patients have converted to CR, bringing the CR rate to 95% (19 of 20). No relapses have been observed to date for patients who have reached CR, and all CRs occurred within one year post-dosing.

Key Details

• CR rate: 95% (19/20) among the first 20 NEXICART-2 patients.
• MRD‑negativity: MRD‑negativity at 10^-5 achieved within 30 days for all MRD‑negative patients.
• Rapid response: As of May 14, 2025, 17 of 20 patients showed rapid normalization of diseased light chains; median time to initial response was 7 days.
• Trial status/timing: NEXICART-2 is fully enrolled (45 patients); next update expected late September 2026. A multi-center, randomized Phase 3 in newly diagnosed AL amyloidosis is planned to start in H1 2027.
• Safety: Safety data through May 14, 2026 reported as generally consistent with prior observations.

Why It Matters

• These results signal strong early efficacy signals for NXC-201 in a difficult-to-treat disease: high CR rates, rapid depth of response (MRD‑negativity at 10^-5), and no observed relapses among CR patients so far could support further development and regulatory interest, especially given the trial’s potentially registrational design.
• Important caution: the company explicitly notes these are interim data. Final trial outcomes may differ, and regulators or third parties may interpret the data differently. Investors should weigh the promising interim results against the risks inherent in ongoing clinical trials.